For the Quarter Ending March 2025
North America
Amphotericin B prices in the USA declined consistently throughout Q1 2025, driven by a convergence of economic headwinds, seasonal disruptions, and geopolitical uncertainties. In January, weakening consumer confidence and severe winter storms slowed downstream pharmaceutical demand and hampered logistics, while preemptive stockpiling—driven by tariff concerns and seasonal procurement—led to an oversupplied market.
February saw further price declines as post-holiday production recovery in China increased export availability, while lower transpacific freight costs sustained inbound supply. However, soft demand persisted amid economic caution, inflation concerns, and delays in ordering due to tariff anxieties.
By March, market conditions worsened as elevated inventories, restrained purchases, and President Trump’s tariff hike on Chinese imports—plus threats against Indian pharmaceuticals—amplified uncertainty. The weakened U.S. dollar added cost pressure to imports, discouraging restocking. As a result, sellers resorted to aggressive price cuts to offload surplus stock.
Throughout the quarter, market sentiment remained subdued with no strong recovery in demand, leading to sustained downward pricing momentum.
Asia Pacific
Amphotericin B prices in China showed a modest rise in January but declined through February and March, resulting in an overall downward trend for Q1 2025. January’s slight increase was driven by steady demand from pharmaceutical and healthcare sectors, limited production ahead of the Lunar New Year, and advance orders amid tariff concerns. However, prices began to fall in February as manufacturers resumed operations post-holiday, boosting output and leading to ample supply. Weak domestic demand, combined with reduced export competitiveness due to U.S. tariffs and a stronger yuan, contributed to growing inventories. The economic environment further dampened buying sentiment, with deflationary pressures and sluggish downstream activity discouraging procurement. In March, production remained strong as firms prepared for summer maintenance, while continued inventory buildup prompted suppliers to offer discounts to stimulate sales. Buyers, having stocked up earlier, delayed fresh orders amid ongoing trade uncertainties and weak foreign interest. Overall, despite early quarter stability, persistent supply-demand imbalance, tariff-related challenges, and muted market activity led to a net decrease in Amphotericin B prices in China during Q1 2025.
Europe
In Q1 2025, Amphotericin B prices in Germany declined consistently due to persistent market imbalances. January marked the beginning of this downward trend, driven by deteriorating consumer sentiment, inflationary pressures, and political uncertainty ahead of national elections. These factors reduced healthcare and pharmaceutical spending, weakening demand. The prospect of U.S. tariffs on Chinese goods prompted Chinese sellers to target Europe, further heightening competition and pressuring prices. In February, the decline continued amid ample supply and subdued demand. The appreciating Euro, along with a steep fall in ocean freight rates on Asia-Europe routes, supported cost-effective imports, resulting in inventory buildup. Early stockpiling ahead of the Lunar New Year kept the market oversupplied. In March, these conditions persisted, with oversupply exacerbated by favorable import economics and healthy shipping capacity. Demand remained muted as buyers prioritized inventory clearance. Despite some port congestion in Europe, falling freight rates and a strong Euro kept landed costs low, reinforcing the soft pricing environment. Throughout Q1, weak domestic sentiment and cautious procurement strategies sustained the downward pressure on Amphotericin B prices in the German market.
For the Quarter Ending December 2024
North America
In Q4 2024, the U.S. Amphotericin B market experienced notable price fluctuations due to a combination of economic conditions and market developments. October saw a decline in prices, largely driven by economic uncertainty, inflation concerns, and weakened consumer demand. A cautious approach from both businesses and consumers, along with external disruptions like hurricanes and strikes, prompted suppliers to lower prices to stimulate sales.
In November, the decline slowed to a minor decrease, as demand continued to soften. A reduction in inflationary pressures and the appreciation of the U.S. dollar helped make imports more affordable. With supply chain issues resolving and inventories remaining well-stocked, prices stabilized and remained relatively steady through the month.
By December, prices began to rise again, fueled by strong demand, proactive purchasing, and the easing of interest rates, which boosted consumer confidence. Anticipation of potential supply disruptions, including strikes and tariffs on Chinese imports, led to increased stockpiling, further driving prices higher as businesses prepared for future cost increases. By the end of the quarter, Amphotericin B was priced at USD 765,000 per metric ton CFR Houston.
Asia Pacific
During Q4 2024, Amphotericin B prices in China experienced fluctuating patterns, influenced by a mix of domestic and global factors. In October, prices saw a slight dip, largely driven by weak domestic demand and an oversupply of stock. Increased competition among suppliers added to the pressure, while geopolitical uncertainties, particularly surrounding the U.S. elections and rising protectionism, suppressed international demand and further contributed to the price decline. The trend persisted into November, with sluggish domestic consumption, high distributor inventories, and a downturn in global sales weighing on prices. Additionally, concerns about impending tariffs fueled uncertainty, keeping the market on edge and preventing any significant recovery. However, December brought a shift as prices began to rise. Strong demand in the pharmaceutical and healthcare sectors, coupled with proactive inventory accumulation ahead of the Chinese Lunar New Year, gave the market a boost. A weaker yuan also made Chinese exports more competitive, further stimulating demand. By the end of Q4, Amphotericin B was priced at USD 733000 per metric ton in China. The quarter's price movement highlighted the market's sensitivity to both domestic demand shifts and international trade dynamics.
Europe
In Q4 2024, Amphotericin B prices in Germany experienced a mix of fluctuations, shaped by a variety of economic and logistical influences. October saw a price decrease, driven by weaker consumer demand amid inflation concerns and a significant reduction in shipping costs, with container prices on Asia-Europe routes dropping by 60%. Businesses adapted by adjusting their logistics strategies, which helped maintain a steady supply, supporting price stability. By November, the market showed signs of stabilization, with only a minor decline in prices. The lingering effects of weak demand and the easing of inflation concerns were still evident, but Germany's economic slowdown and a 1.9% drop in energy costs kept prices in check. Suppliers with well-stocked inventories were able to offer competitive rates, preventing any major shifts in pricing. December brought a reversal, with prices rising due to increased demand from key sectors and logistical challenges ahead of the Chinese Lunar New Year. The weakening Euro and port congestion in Europe further strained supply chains, adding upward pressure on prices. By the end of Q4, Amphotericin B was priced at USD 766,000 per metric ton CFR Hamburg.
For the Quarter Ending December 2022
North America
During the fourth quarter of 2022, Amphotericin B market dynamics fluctuated in the North American region. Prices were expected to increase starting in Q4 2022 and continuing through the second month of the quarter as a result of a high cost of manufacturing, numerous logistical issues, and rising inflation.
Rising transportation costs and port congestion at the key ports also helped to keep the market position strong. A slowdown in API output, disorganization, and rising energy prices all had a positive effect on the market. Due to easing inflation and reducing end-user sector demand, prices started to decline later in December 2022. Values were accessed at USD 6265400/MT CFR Houston at the end of Q4 with an average quarterly inclination of 0.40%.
APAC
During the fourth quarter of 2022, the Amphotericin B market in the Asia-Pacific region showed a general downward trend. Amphotericin B costs have decreased quarterly due to reduced demand from the terminal pharmaceutical sector. An economy that was slowing down, plentiful supplies, and plenty of stocks supported this consistent pricing pattern. Later in December, prices significantly dropped as a result of a dip in domestic and international market inquiries brought on by the approaching holiday and festive season. The market was also impacted by sufficient supply and inventory levels. Towards the termination of Q4 2022, the values accessed at USD 6150500/MT with a quarterly declination of 0.15%.
Europe
In the European market, Amphotericin B prices followed an uptrend in the fourth Quarter of 2022 amidst soaring energy coast and squeezed manufacturing profit margins. Values were accessed at USD 6383940/MT at the end of Q4 2022, with an average quarterly incline of 0.61%. Inflation in the eurozone was recorded to reach a new high of 10.7% in October from 9.6% recorded in September. The price of natural gas for household consumers soared, influencing the market situation. Also, increased production costs kept the market sentiments robust. Later, from the second month of Q4, the prices were witnessed to follow the stable trajectory on the stable back demand from the end-user sector and enough inventories among the domestic merchants.
For the Quarter Ending September 2022
North America
In the third quarter of 2022, Amphotericin B pricing patterns have seen a declining trend in the North American market. The hindered global trade operations have significantly impacted the price chain of Amphotericin B in the regional market. Due to decreased demand from the end-user industry and growing inflation, Amphotericin B's diminishing market values among dealers have been further supported. The cost was USD 6192500/MT at the end of Q3 2022, with a 2.42% decline in the average quarterly cost. Amphotericin B prices decreased in the third quarter across the local market due to lower production and input costs.
APAC
The Asia-Pacific region's Amphotericin B market declined during the third quarter of 2022. The quarter-long decline in Amphotericin B prices results from weak demand from the terminal pharmaceutical industry. This downward price trend was backed by a slowing economy, enough supplies, and ample stocks. Prices dramatically climbed towards the end of the second half of Q3 due to an increase in domestic and foreign market inquiries. A limited supply also impacted the market in the previous month due to the last production halts, trade activities after lousy weather, and zero covid policies. Weak demand fundamentals and consistent supply drove the Amphotericin B market's negative trajectory. Towards the termination of Q3 2022, the values accessed at USD 6180500/MT with a quarterly declination of 1.32%.
Europe
Due to weak downstream pharmaceutical demand dynamics, the market for Amphotericin B shrank in the third quarter of 2022. Values were accessible at USD 6268960/MT at the end of Q3 2022, with an average quarterly decline of 3.70%. The declining offtakes from the regional market, which resulted in subdued trading dynamic, were another factor that caused the values to plunge. The end-user supplier and dealers haggled over their already-stockpiled commodities to retain their profit margins. Operating costs, raw material prices, and purchasing activity all decreased slightly. All of these factors contributed to the declining market dynamics and the downward movement of Amphotericin B's price.
